Atum, Phylex accelerate universal SARS coronavirus vaccine

By The Science Advisory Board staff writers

Atum and Phylex BioSciences will collaborate to advance research toward creating a universal vaccine effective against pathogenic coronaviruses, including the novel coronavirus SARS-CoV-2.

Through the partnership, Atum will utilize its Leap-in-Transposase platform to develop the cell line required for Phylex's universal severe acute respiratory syndrome (SARS) coronavirus vaccine candidate.

The Phylex antigen candidate contains epitopes similar to the receptor-binding domain of the SARS coronavirus spike protein. Copies of the antigen are displayed on a virus-like particle that self-assembles after being secreted by the cell line in development by Atum.

The collaboration will enable Phylex to develop the vaccine candidate while simultaneously conducting immunogenicity studies, noted co-founder and Chief Executive Officer Pascal Brandys in a press release. Brandys added that the company's objective is to develop a universal vaccine candidate with an associated manufacturing and clinical development plan by fall 2020.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking